Akeso's Upcoming Conference Participation
Akeso, Inc. (9926.HK) announces its participation at two prominent events in the healthcare sector. The 7th Annual Evercore HealthCONx Conference and the Citi 2024 Global Healthcare Conference are highly anticipated gatherings that offer industry leaders a platform to showcase their latest innovations and share insights into the future of healthcare.
Details of the Events
The company will participate in a dynamic fireside chat at the 7th Annual Evercore HealthCONx Conference. This engaging session is scheduled for December 4, providing attendees an in-depth look into Akeso's groundbreaking work in biopharmaceuticals. Additionally, Akeso is set to participate in a fireside chat at the Citi 2024 Global Healthcare Conference on December 5. These discussions will occur in the morning, highlighting the company's commitment to ongoing advancements in healthcare solutions.
About Akeso
Established in 2012, Akeso stands at the forefront of the biopharmaceutical industry. With its unique integrated R&D innovation system, the company has built a comprehensive end-to-end drug development platform known as the ACE Platform. This advanced system is complemented by its bi-specific antibody drug development technology, known as Tetrabody. Akeso is recognized for its aggressive pursuit of innovative biological medicines, aiming to develop the world's first or best-in-class treatments.
Innovative Approach and Pipeline
Through strategic innovation and efficiency in research and development, Akeso has established itself as a globally competitive entity in biopharmaceutical creation. The company boasts a robust pipeline of over 50 innovative assets targeting various ailments such as cancer and autoimmune diseases. Notably, 22 of these candidates have already entered clinical trials, which include 11 bispecific/multispecific antibodies.
Regulatory Approvals and Market Entries
Being proactive, Akeso has five new drugs commercially available, with five additional treatments currently undergoing regulatory review across seven different indications. The potential approval of these substances marks a significant leap forward in providing affordable therapeutic options for patients around the world.
Continuous Commitment to Better Health
Akeso’s vision is clear: to provide cutting-edge, cost-effective therapeutic antibodies and continually enhance the social and commercial value within the biopharmaceutical landscape. By harnessing global resources and committing to research excellence, Akeso endeavors to become a leading name in patient care, championing innovative solutions that address major health issues. Their participation in these conferences further underscores their dedication to driving advancements in biopharmaceutical development.
Frequently Asked Questions
What conferences is Akeso participating in?
Akeso will take part in the 7th Annual Evercore HealthCONx Conference and the Citi 2024 Global Healthcare Conference.
When will Akeso present at these conferences?
The fireside chat at the Evercore Conference is scheduled for December 4, and the Citi Conference will feature Akeso on December 5.
What is Akeso known for?
Akeso is recognized for its commitment to researching and developing innovative biological medicines, particularly in fields like cancer and autoimmune diseases.
How many drugs does Akeso have in clinical trials?
Currently, 22 candidates within Akeso’s pipeline are undergoing clinical trials, focusing on innovative treatment options.
What are Akeso's future goals in biopharmaceuticals?
Akeso aims to continuously develop the first-in-class and best-in-class therapies while maintaining affordability for patients worldwide.
